Biotech Values

[poorgradstudent]

The article you linked to argues the comparatively high PAP expression in prostate tissues make it a differentiation antigen and a better target than say a ubiquitous antigen like HER2 where high affinity T cells aren't going to exist.

This is a good comment. I wish these vaccine companies that run phase 3 trials would share some basic info regarding patient response to the antigen. For example, how about just a simply blood draw and antibody response by ELISA or something? A waterfall plot of all patients treated with the antigen and how they measured on a simple immune response parametre?

Usually the last we see of that type of data is from a responder subgroup in phase 2.